ArticlePediatric transplantation2025
Liposomal Bupivacaine in Single-Injection Quadratus Lumborum Block for Pediatric Kidney Transplant: Case Report of a Novel Application.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regional Anaesthesia Techniques in Liver and Kidney Transplantation: A Narrative Review in Donors and Recipients.Turkish journal of anaesthesiology and reanimation · 2026Article
- Ultrasound-Guided Multilevel Bilateral Rectus Sheath Blocks with Liposomal Bupivacaine, Bupivacaine, and Dexamethasone PF for Postoperative Pain Management After a Pediatric Abdominal Aortic Aneurysm Repair.Children (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiposomal bupivacaine is FDA-approved long-acting bupivacaine for intraoperative local wound infiltration in pediatric patients 6 years and older, but not for ultrasound-guided peripheral nerve blocks. There are few prior reports of using liposomal bupivacaine for preoperative peripheral nerve blocks in pediatric patients. We report the first use of liposomal bupivacaine in a single-injection quadratus lumborum block in a pediatric patient undergoing a kidney transplant.
methodsOur patient is a 16-year-old female undergoing a living-related kidney transplant for end-stage renal disease. Pertinent past medical history includes symptoms of opioid withdrawal during a prior hospitalization. To optimize postoperative pain control, a preoperative single injection quadratus lumborum nerve block was performed with liposomal bupivacaine, and opioids and acetaminophen were administered as needed in the perioperative period.
resultsThe patient had excellent pain control for the first 36 h postoperatively and adequate pain control for the entire hospital stay, with minimal opioid administration. She reported decreased sensation to temperature and touch over her entire ipsilateral abdomen/flank for the first 48 h. Postoperative day 4 marked her highest average pain score, coinciding with the reported 72 h of efficacy of liposomal bupivacaine. She was able to ambulate less than 24 h postoperatively, did not report any withdrawal symptoms, and had no adverse events.
conclusionsThis is the first documented case of liposomal bupivacaine in a preoperative quadratus lumborum nerve block for a pediatric patient. More studies are required to investigate the pharmacokinetics of liposomal bupivacaine in kidney recipients and determine its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.